Owens & Minor (NYSE: OMI) stock plummeted 8.32% in pre-market trading on Monday following the release of its second-quarter 2025 financial results, which fell short of analysts' expectations. The healthcare solutions company reported Q2 revenue of $681.9 million, significantly below the consensus estimate of $2.73 billion, while adjusted earnings per share came in at $0.26, missing the expected $0.27.

The dramatic difference in revenue figures is largely due to Owens & Minor's classification of its Products & Healthcare Services segment as discontinued operations, reflecting an impending sale of this business unit. This major restructuring has transformed the company into a pure-play Patient Direct business, focusing on what was previously known as the Patient Direct segment. The move has significantly altered the company's financial reporting, making year-over-year comparisons challenging.

Despite the market's negative reaction, Owens & Minor's management expressed optimism about the company's future. CEO Ed Pesicka highlighted favorable demographic trends and the company's meaningful scale as factors supporting its growth and leadership in the evolving market. However, investors appear concerned about the short-term impact of the restructuring and the missed earnings expectations. The company plans to provide its 2025 financial outlook for continuing operations during an upcoming earnings conference call, which may offer more clarity on its future prospects.